Introduction
============

Mycalolides have been isolated from marine sponges of the genus of *Mycale* \[[@b1-marinedrugs-03-00029]--[@b3-marinedrugs-03-00029]\] and the hard coral *Tubastrea faulkneri* \[[@b4-marinedrugs-03-00029]\], and their structures are elucidated to be macrocyclic lactones characterized with an unusual tris-oxazole moiety and *N*-methylformyl terminus. So far, kabiramides \[[@b5-marinedrugs-03-00029]\], ulapualides \[[@b6-marinedrugs-03-00029]\], halichondramides \[[@b7-marinedrugs-03-00029]\], and jaspamides \[[@b8-marinedrugs-03-00029]\] are known as structurally related metabolites. Mycalolides A--C exhibited significant cytotoxicity against B-16 melanoma cells \[[@b1-marinedrugs-03-00029]\] and potent actin depolymerizing activity \[[@b9-marinedrugs-03-00029]\]. The ubiquitin-proteasome proteolytic pathway plays a major role in selective protein degradation and regulates various cellular events including cell growth and apoptosis \[[@b10-marinedrugs-03-00029]--[@b13-marinedrugs-03-00029]\]. Ubiquitin, composed of 76 amino acids, attaches to a target protein prior to degradation. The polyubiquitin chains are recognized by the 26S proteasome, an intracellular high-molecular mass protease subunit complex, and the protein portion is degraded by the proteolytic active sites in a cavity in the 26S proteasome \[[@b10-marinedrugs-03-00029], [@b11-marinedrugs-03-00029]\]. Several proteasome inhibitors show anti-tumor activity against various tumor cells that are resistant to conventional chemotherapeutic agents. Proteasome inhibitors have been reported to inhibit the degradation of Iκ-B followed by suppression of NF-κB transcriptional activity to induce apoptosis \[[@b14-marinedrugs-03-00029]\]. To date, synthetic peptides, such as MG132 \[[@b15-marinedrugs-03-00029]\] and PS-341 (bortezomib, Velcade^®^) \[[@b16-marinedrugs-03-00029]\], and natural products, including lactacystin \[[@b17-marinedrugs-03-00029]--[@b19-marinedrugs-03-00029]\], epoxomycin \[[@b20-marinedrugs-03-00029], [@b21-marinedrugs-03-00029]\], and salinosporamide A \[[@b22-marinedrugs-03-00029]\], have been reported to inhibit proteasome activity. Among them, PS-341 has been recently approved by FDA for multiple myeloma treatment \[[@b23-marinedrugs-03-00029]\]. Interestingly, different classes of proteasome inhibitors can differentially affect the degradation of various proteasome substrates, resulting in diverse cellular responses \[[@b14-marinedrugs-03-00029]\]. Proteasome inhibitors are now under intensive investigation not only for anti-cancer drugs but also for drugs to treat inflammatory and immune deficiency diseases \[[@b24-marinedrugs-03-00029]\]. In the course of our search for inhibitors against the ubiquitin-proteasome pathway, we succeeded in isolating new agosterol derivatives \[[@b25-marinedrugs-03-00029]\] and a pyrone derivative named himeic acid A \[[@b26-marinedrugs-03-00029]\] as proteasome inhibitors and a ubiquitin-activating enzyme (E1) inhibitor, respectively. In addition, we found that girolline, an anti-cancer compound, is the first agent inhibiting the recruitment of polyubiquitinated p53 to the proteasome \[[@b27-marinedrugs-03-00029]\]. In this paper, we describe the isolation, structure elucidation, and proteasome inhibitory activity of three mycalolides.

Results and Discussion
======================

The MeOH extract of a sponge collected from shallow waters off Sugashima Island 130 km southeast of Osaka was subjected to solvent partitioning between EtOAc and water. The active EtOAc fraction was further partitioned between *n*-hexane and 90% MeOH/H~2~O, and the latter fraction was purified by ODS chromatography and ODS HPLC to afford a new mycalolide derivative, secomycalolide A (**1**) together with known mycalolide A (**2**) \[[@b1-marinedrugs-03-00029]\] and 30-hydroxymycalolide A (**3**) \[[@b2-marinedrugs-03-00029]\].

The ^1^H NMR spectrum of **1** in CDCl~3~ ([Table 1](#t1-marinedrugs-03-00029){ref-type="table"}) showed two low-field heteroaromatic protons (δ 7.77 and 8.50), a pair of formamides for the major and minor rotational isomers (δ 8.30 and 8.08, intensity 5:3), three *E*-olefines (δ 5.98/6.84, 6.25/7.00, and 6.50/4.97), six oxygene-bearing protones δ 2.99, 3.58, 4.22, 4.34, 5.16, and 5.22), four *O*-methyls (δ 3.19, 3.30, 3.45, and 4.05), a pair of *N*-methyls (δ 3.03 and 3.08), an acetoxy methyl (δ 2.01), and five doublet methyls (δ 0.84, 0.93, 0.94, 1.05, and 1.07). These data readily suggested that **1** was a congener of mycalolide A (**2**). Comparison of the ^1^H NMR spectrum of **1** with that of **2** showed the absence of an oxazole proton in the region of δ 7.5--8.6 instead of the presence of an additional *O*-methyl at δ 4.05. These data indicated that **1** was a seco-oxazole derivative of **2**, which was supported by the molecular formula of **1**, C~47~H~68~N~4~O~16~ established by HRFABMS, a H~4~O~2~ unit more than **2**. So far three seco-oxazole halichondramides were isolated and are known as halishigamides C (**4**) and D (**5**) \[[@b28-marinedrugs-03-00029]\] and halichondramide ester (**6**) \[[@b7-marinedrugs-03-00029]\]. By comparison of their ^1^H NMR data, the signals for the olefin group at δ 5.98/6.84 (H-19/H-20) in **1** were matched with those in **6** (δ 5.89/6.85). On the contrary, the olefin protons in **4** and **5** were observed at δ 6.37/6.84 (H-19/H-20) and δ 6.31/6.76 (H-19/H-20), respectively. Since H-19 in **1** and **6** corresponded to the α--position in an α,β-unsaturated methyl ester system, they revealed the up-field shift compared to those of **4** and **5**, in which H-19 was bonded to an oxazole ring. Thus, the structure of **1** was defined to be a seco-oxazole derivative of mycalolide A as shown \[[@b29-marinedrugs-03-00029]\].
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The proteasome displays multicatalytic activities, e.g. chymotrypsin-like, trypsin-like, and peptidylglutamyl-peptide hydrolyzing activities. Inhibitory activities of three mycalolides were tested using a chymotrypsin-like substrate, and the IC~50~ values of **1**, **2**, and **3** were found to be 11, 30, and 45 μg/mL, respectively.

Conclusion
==========

We have isolated a new mycalolide derivative secomycalolide A (**1**) together with known mycalolide A (**2**) and 30-hydroxymycalolide A (**3**). They showed moderate inhibitory activities against chymotrypsin-like activity of the proteasome. Among three mycalolides, seco-oxyazole derivative **1** showed the most potent inhibitory activity. So far, cytotoxicity \[[@b1-marinedrugs-03-00029]\] and potent actin depolymerizing activity \[[@b9-marinedrugs-03-00029]\] of mycalolides have been reported; however, this is the first report of proteasome inhibitory activity of mycalolides.

Experimental
============

General
-------

NMR spectra were recorded on a JEOL GSX500 in CDCl~3~. All chemical shifts were reported with respect to the residual solvent peaks (δ~H~ 7.26). Mass spectra were measured on a JEOL SX-102 mass spectrometer. The fluorescence intensity (excitation, 360 nm; emission, 460 nm) was measured using a BIO-RAD VersaFluor Fluorometer.

Extraction and Isolation
------------------------

A marine sponge of the genus *Mycale* was collected from shallow waters off Sugashima Island 130 km southeast of Osaka. The frozen material (4.2 kg, wet wt) was extracted with MeOH (3 L × 3). The extract was concentrated under reduced pressure and extracted with EtOAc. The EtOAc layer was partitioned between *n*-hexane and 90% MeOH/H~2~O. The aqueous MeOH fraction (2.1 g) was subjected to ODS chromatography with MeOH/H~2~O. The fraction (450 mg) eluted with 80% MeOH/H~2~O was purified by gel filtration on Sephadex LH-20 with CHCl~3~/MeOH (1:1) followed by ODS HPLC with 70% MeOH/H~2~O to afford two active fractions. The first fraction (7.8 mg) was purified by ODS HPLC with 70% CH~3~CN/H~2~O to afford mycalolide A (**2**, 1.51 mg, 3.6 × 10^−5^%, wet weight) and 30-hydroxymycalolide A (**3**, 0.54 mg, 1.3 × 10^−5^%). The second fraction (6.9 mg) was purified by ODS HPLC with 50% CH~3~CN/H~2~O to afford secomycalolide A (**1**, 1.45 mg, 3.5 × 10^−5^%).

**Secomycalolide A (1)**: ^1^H NMR (CDCl~3~), see [Table 1](#t1-marinedrugs-03-00029){ref-type="table"}; FABMS *m/z* 967 \[M + Na\]^+^; HRFABMS *m/z* 967.4553 (calcd for C~47~H~68~N~4~O~16~Na, 967.4528).

Preparation of Proteasome-enriched Fraction
-------------------------------------------

Proteasome used in this study was partially purified from rat liver. The liver was dissected and homogenized in ice-cold lysis buffer consisting of 20 mM HEPES, pH 7.5, 5 mM KCl, 1.5 mM MgCl~2~, 1 mM dithiothreitol, 2 mM ATP, and 10% glycerol at 4 °C for 5 min. The extract was filtered through cheese cloth, and the filtrate was immediately centrifuged at 10,000 rpm for 5 min. The supernatant was centrifuged at 105,000 × g for 20 min, and the resultant supernatant was further centrifuged at 300,000 × g for 2 h. The precipitates thus obtained were suspended in lysis buffer containing 50% glycerol and used as the crude proteasome-enriched preparation.

Assay for Proteasome Activity
-----------------------------

The fluorogenic substrate succinyl-leucyl-leucyl-valyl-tyrosine 4-methylcoumaryl-7-amide (MCA) (Peptide Institute, Inc., Osaka) was used as a substrate for chymotrypsin-like activity of the proteasome. The proteasome-enriched fraction in a mixture (0.1 mL) that contained 50 mM Tris-HCl, pH 7.8, 1 mM dithiothreitol, and 5 mM EDTA was pre-incubated with each inhibitor at 30 °C for 10 min. Then, 0.05 mM substrate was added to the mixture and the mixture was further incubated at 30 °C for 1 h. The reaction was stopped by adding 0.1 mL of 10% SDS and the fluorescence intensity owing to 7-amino-4-methylcoumarin (AMC) was measured (excitation, 360 nm; emission, 460 nm). The value of IC~50~, the concentration required for 50% inhibition of proteasome inhibitory activity, was calculated from the data of duplicate measurements.
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^1^H NMR Data of Secomycalolide A (**1**) in CDCl~3~

  position   δ~H~
  ---------- -------------------------------------------------------------------------------------------------
  2          2.60 m, 2.70 m
  3          4.22 m
  4          2.50 m, 2.50 m
  5          7.00 dt (16.8, 6.6)
  6          6.25 d (16.8)
  8          3.50 m
  8-Me       0.93 d (6.6)
  9          4.34 d (9.0)
  9-OMe      3.19 s
  11         7.77 s
  14         8.50 s
  18-OMe     4.05 s
  19         5.98 d (16.2)
  20         6.84 ddd (16.2, 7.5, 6.0)
  21         2.50 m, 2.75 m
  22         3.58 m
  22-OMe     3.45 s
  23         1.92 m
  23-Me      0.94 d (6.6)
  24         5.22 m
  25         1.55m, 1.60 m
  26         2.99 m
  26-OMe     3.30 s
  27         1.74 m
  27-Me      0.84 d (6.6)
  28         1.25 m, 1.74 m
  29         2.47 m, 2.47 m
  31         2.77 m
  31-Me      1.07 d (6.6)
  32         5.16 dd (9.7, 2.9)
  32-OAc     2.01 s
  33         2.50 m
  33-Me      1.05 d (6.6)
  34         4.97 dd (14.1, 9.4) \[5.00 dd (14.1, 9.4)\][a](#tfn1-marinedrugs-03-00029){ref-type="table-fn"}
  35         6.50 d (14.1) \[7.16 d (14.1)\] [a](#tfn1-marinedrugs-03-00029){ref-type="table-fn"}
  35-NMe     3.03 s \[3.08 s\] [a](#tfn1-marinedrugs-03-00029){ref-type="table-fn"}
  35-NCHO    8.30 s \[8.08 s\] [a](#tfn1-marinedrugs-03-00029){ref-type="table-fn"}

Chemical shifts for the minor conformer are bracketed.
